DrugPatentWatch Database Preview
Litigation Details for Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2011)
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2011)
| Docket | Start Trial | Date Filed | 2011-11-03 |
| Court | District Court, D. Delaware | Date Terminated | 2014-09-17 |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Parties | ACTAVIS INC.; ACTAVIS SOUTH ATLANTIC LLC; ACTAVIS, INC.; LTS LOHMANN THERAPIE-SYSTEME AG; NOVARTIS AG; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.; NOVARTIS PHARMA AG; NOVARTIS PHARMACEUTICALS CORPORATION; PAR PHARMACEUTICAL INC.; WATSON LABORATORIES INC.; WATSON PHARMA INC.; WATSON PHARMACEUTICALS INC. | ||
| Patents | 6,316,023; 6,335,031; 6,699,498 | ||
| Attorneys | Andrea M. Houston; C. Nicole Gifford; Daniel G. Brown; Daniel M. Silver; Dominick T. Gattuso; Erika R. Caesar; Erin A. Thomson; Gina R. Gencarelli; Jaclyn C. Levy; James L. Higgins; Jennifer Koh; Katharine Crawford Lester; Melanie K. Sharp; Michael P. Kelly; Michelle R. Ma; Robert M. Vrana; Stephen M. Hash; Steven J. Fineman | ||
| Firms | Ballard Spahr LLP; Friedlander & Gorris, P.A.; Proctor Heyman LLP; Richards, Layton & Finger, PA; Young, Conaway, Stargatt & Taylor LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc.
The small molecule drugs covered by the patents cited in this case are Start Trial and Start Trial .
Details for Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2011)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2013-11-01 | 319 | is not an oxidizing environment L`§.S poteet 6,699,498 (the “L'l`S petent’”‘), assigned to ]§*.§e…et limited States patents 6,3 35. l(“°OB] patent ) and 6 ,.3]6 {}23 (_ “’GZB patent ’) {_e~t)§leetivety…far below the threshold set by the LTS patent 'i`hc patents in colt also z‘ecognize that “co'l.npound…Composition” Ciaims {3 and 7 of the ’031 patent and 2 and 7 of the . ’{323 patent) I.~ ’}"here is No Evidenee…quot;’ C1aims (3 and 7 0'1" 1110 ’{)3 1 patent and 2 and 7 of the "023 paf‘enf) ........ | External link to document | |
| 2014-06-18 | 40 | detecting peroxides. U.S. Patent No. 6,699,498, 2:58- 62 ("the '498 patent") ("The peroxide…the '023 patent") (collectively, "the patents in suit"). Both patents share the same…that the patent examiner for the '023 and '031 patents considered both the '807 patent and U.S…alleging infringement of U.S. Patent Nos. 6,335,031 ("the '031 patent") and 6,316,023 ("…16, and 18 of the '031 patent and claims 2 and 7 of the '023 patent. Watson counters that the | External link to document | |
| 2014-06-18 | 414 | detecting peroxides. U.S. Patent No. 6,699,498, 2:58- 62 ("the '498 patent") ("The peroxide…the '023 patent") (collectively, "the patents in suit"). Both patents share the same…that the patent examiner for the '023 and '031 patents considered both the '807 patent and U.S…alleging infringement of U.S. Patent Nos. 6,335,031 ("the '031 patent") and 6,316,023 ("…16, and 18 of the '031 patent and claims 2 and 7 of the '023 patent. Watson counters that the | External link to document | |
| 2014-08-29 | 426 | infringement of U.S. Patents Nos. 6,335,031 ("the '031 patent") and 6,316,023 ("the '…#39;023 patent") (collectively, "the patents in suit"). Both patents share the same specification…Par's ANDA products infringe claim 7 of the '031 patent. Par should submit an agreed upon form of final…). 3 Novartis listed the '031 and '023 patents in the Food and Drug Administration's "…citations to the specification refer to the '031 patent. 3 Unless otherwise noted, all citations to the | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
